Supercharged immune cells take on Hard-to-Treat lung cancer
NCT ID NCT05681780
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new approach for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). Doctors take immune cells from the patient's own tumor, boost them in the lab with a molecule called CD40L, and then give them back along with the immunotherapy drug nivolumab. The goal is to see if this combination is safe and can shrink tumors. The study is currently recruiting 20 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tumor-infiltrating lymphocytes (TIL) boosted with CD40L, plus nivolumab (Opdivo), cyclophosphamide, and fludarabine
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced lung cancer that has specific gene changes and has stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 20 participants, so it is primarily testing safety, not effectiveness. The treatment involves strong chemotherapy and immune therapy, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?